Clinical Trial Update: Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is investigating whether dapagliflozin can activate autophagy and suppress apoptosis to attenuate inflammatory bowel disease, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease

Drugs mentioned

• Dapagliflozin (Farxiga) (dapagliflozin)

Snippet

Sponsor: Mostafa Bahaa | Conditions: Inflammatory Bowel Diseases | Phase 2, Phase 3 | Status: RECRUITING